IMODIUM A-D EZ CHEWS Drug Patent Profile

When do Imodium A-d Ez Chews patents expire, and what generic alternatives are available?

Imodium A-d Ez Chews is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in IMODIUM A-D EZ CHEWS is loperamide hydrochloride. There are eleven drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imodium A-d Ez Chews

A generic version of IMODIUM A-D EZ CHEWS was approved as loperamide hydrochloride by MYLAN on September 18^th, 1991.

Summary for IMODIUM A-D EZ CHEWS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	25
Patent Applications:	3,096
DailyMed Link:	IMODIUM A-D EZ CHEWS at DailyMed

Recent Clinical Trials for IMODIUM A-D EZ CHEWS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MedSIR	Phase 2
Gilead Sciences	Phase 2
9 Meters Biopharma, Inc.	Phase 1/Phase 2

See all IMODIUM A-D EZ CHEWS clinical trials

US Patents and Regulatory Information for IMODIUM A-D EZ CHEWS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997		DISCN	Yes	No

Expired US Patents for IMODIUM A-D EZ CHEWS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997

International Patents for IMODIUM A-D EZ CHEWS

See the table below for patents covering IMODIUM A-D EZ CHEWS around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0523847	Enrobage masquant le mauvais goût pour la préparation de comprimés à mâcher pharmaceutiques (Taste mask coating for preparation of chewable pharmaceutical tablets)
Canada	2068402	ENROBAGE POUR MASQUER LE GOUT POUVANT ETRE UTILISE DANS DES COMPRIMES PHARMACEUTIQUES CROQUABLES (TASTE MASK COATINGS FOR PREPARATION OF CHEWABLE PHARMACEUTICAL TABLETS)
Spain	2089403
Germany	69210124

Supplementary Protection Certificates for IMODIUM A-D EZ CHEWS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0428296	SPC/GB98/013	United Kingdom		PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923

IMODIUM A-D EZ CHEWS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Imodium A-D EZ Chews

Introduction to Imodium A-D EZ Chews

Imodium A-D EZ Chews are a part of the Imodium brand, which is widely recognized for its anti-diarrheal medications. These chewable tablets are designed to provide quick and effective relief from diarrhea, including traveler's diarrhea, and are manufactured by Janssen Pharmaceuticals Inc. and Johnson and Johnson Consumer Inc.[5].

Market Position and Brand Reputation

Imodium is the #1 doctor-recommended anti-diarrheal brand, which significantly influences its market position. The brand's reputation for fast and effective relief has been built over decades, with Imodium A-D products being available over-the-counter in the United States since 1988[2].

Consumer Trust and Loyalty

The trust and loyalty of consumers are crucial factors in the market dynamics of Imodium A-D EZ Chews. The brand's long history and consistent performance have established a strong customer base. Consumers often prefer Imodium due to its proven formula and the convenience of its various forms, including liquid, caplets, softgels, and EZ Chews[1][3][4].

Product Variations and Target Market

Product Forms

Imodium offers several product forms to cater to different consumer preferences and needs. The EZ Chews are particularly popular among parents for their children due to their ease of use and palatable flavor. This variety helps in capturing a broader market share, including both adults and children aged 6 and older[3][4].

Target Market

The target market for Imodium A-D EZ Chews includes individuals suffering from acute or traveler's diarrhea. This encompasses a wide demographic, from travelers to families with young children. The product's effectiveness and ease of administration make it a preferred choice for many[1][3].

Financial Performance

Revenue and Sales

Imodium, as a brand, generates significant revenue due to its widespread use and market dominance. While specific financial figures for Imodium A-D EZ Chews alone are not publicly disclosed, the overall success of the Imodium brand contributes substantially to the revenue of its manufacturers, Janssen Pharmaceuticals Inc. and Johnson and Johnson Consumer Inc.[5].

Market Share

As the #1 doctor-recommended anti-diarrheal brand, Imodium holds a considerable market share in the anti-diarrheal medication sector. This market share is maintained through continuous marketing efforts, product innovation, and the trust built over years of reliable performance[2].

Regulatory and Safety Considerations

FDA Actions and Safety Alerts

The FDA has issued several safety alerts regarding the use of Imodium, particularly concerning the risks associated with overdosing. In 2016, the FDA warned about the dangers of accidentally or intentionally overdosing on loperamide, which can lead to serious cardiac issues. This has led to increased vigilance in marketing and labeling, ensuring users are aware of the potential risks[2].

Impact on Sales

While regulatory actions and safety alerts can potentially impact sales, Imodium's strong brand reputation and the critical need for effective anti-diarrheal medications have helped mitigate any significant negative effects. Manufacturers have adapted by including clear warnings and guidelines on the product labels to ensure safe use[2].

Legal and Litigation Aspects

Lawsuits and Compensation

There have been lawsuits related to Imodium, particularly concerning cardiac issues resulting from misuse or overdose. These lawsuits seek compensation for medical treatment, lost wages, pain and suffering, and in some cases, punitive damages. While these legal challenges can affect the financial trajectory, they are managed through legal representation and settlements[2][5].

Marketing and Distribution

Distribution Channels

Imodium A-D EZ Chews are widely available through various distribution channels, including pharmacies, retail stores, and online platforms. This broad availability ensures that the product reaches a wide audience, contributing to its financial success[1][4].

Marketing Strategies

The marketing strategies for Imodium A-D EZ Chews focus on highlighting the product's effectiveness, convenience, and the trust associated with the Imodium brand. Advertising campaigns often target parents and travelers, emphasizing the quick relief and ease of use of the product[1][4].

Future Outlook

Market Trends

The demand for anti-diarrheal medications is expected to remain steady, driven by the ongoing need for effective treatments for acute and traveler's diarrhea. The convenience and effectiveness of Imodium A-D EZ Chews position them well to continue capturing a significant share of this market[3].

Product Innovation

To maintain market dominance, the manufacturers of Imodium are likely to continue innovating and improving their products. This could include new flavors, formulations, or additional features that enhance user experience and safety[1][4].

Key Takeaways

• Market Dominance: Imodium A-D EZ Chews benefit from the strong brand reputation and market dominance of the Imodium brand.
• Consumer Trust: The trust and loyalty of consumers are crucial for the product's financial success.
• Regulatory Compliance: Ensuring compliance with FDA guidelines and safety alerts is essential to maintain consumer confidence.
• Legal Considerations: Managing lawsuits and ensuring clear labeling can mitigate potential financial impacts.
• Marketing Strategies: Effective marketing focusing on convenience, effectiveness, and brand trust is vital for continued success.

FAQs

What is Imodium A-D EZ Chews used for?

Imodium A-D EZ Chews are used to treat symptoms of diarrhea, including traveler's diarrhea, in adults and children aged 6 and older[3].

What are the active ingredients in Imodium A-D EZ Chews?

The active ingredient in Imodium A-D EZ Chews is loperamide hydrochloride, with 1 mg in every 7.5 mL or each chewable tablet[1][3].

Can Imodium A-D EZ Chews be used by children under 6 years old?

No, Imodium A-D EZ Chews are intended for children aged 6 and older. For children between 2 to 5 years, use is only recommended if advised by a doctor[3].

What are the potential cardiac risks associated with Imodium A-D EZ Chews?

Taking more than the recommended dose of Imodium A-D EZ Chews can lead to serious cardiac issues, including abnormal heart rhythms and other cardiac conditions[2].

How do regulatory actions impact the sales of Imodium A-D EZ Chews?

Regulatory actions and safety alerts have led to increased vigilance in marketing and labeling, but the strong brand reputation and critical need for the product have mitigated any significant negative effects on sales[2].

Sources

1. Rite Aid: Imodium A-D Liquid Oral Anti-Diarrheal Medicine - Mint, 8 fl oz.
2. AutoAccident.com: Imodium and Cardiac Issues.
3. Medical News Today: Imodium: Dosage, uses, side effects, how it works, and more.
4. Target: Imodium A-d Digestive Health Liquid - 4 Fl Oz.
5. Parker Waichman LLP: Imodium Lawsuit Lawyers.